fibrosierende

Fibrosierende is a German adjectival form meaning "fibrosing" or "undergoing fibrosis." In medical and scientific contexts it describes tissues or processes in which excess fibrous connective tissue develops, often as a response to chronic injury, inflammation, or aberrant repair mechanisms. The term is frequently used in compound phrases (for example, fibrosierende Veränderungen) to characterize progressive scarring in organs.

Pathologically, fibrosierende changes involve activation of fibroblasts and myofibroblasts, deposition of extracellular matrix proteins such as collagen, and remodeling of normal tissue architecture. These processes can occur in many organs, including the lungs (pulmonary fibrosis), liver (cirrhosis), heart (cardiac fibrosis), and kidneys (renal fibrosis), and they are associated with impaired organ function and increased morbidity.

Causes are diverse and include persistent inflammation, autoimmune disease, environmental exposures, infections, certain medications, radiation, and genetic predisposition. Diagnosis of fibrosierende conditions relies on clinical assessment supported by imaging (high-resolution CT for the lung, ultrasound or MRI for other organs), laboratory tests, and often histological examination of biopsy specimens.

Management aims to halt or slow progression, preserve function, and treat complications. Approaches include removal or treatment of the underlying cause, anti-inflammatory and antifibrotic medications (for example, agents used in idiopathic pulmonary fibrosis), symptomatic therapy, and, in advanced cases, organ transplantation. Research continues into molecular mechanisms and targeted antifibrotic therapies.